ClinicalTrials.gg
CompletedNCT02278367Updated Sep 10, 2020Results posted

Clinical Evaluation of Flortaucipir F 18

A Phase 2 interventional study of Flortaucipir F18 and Brain PET scan in Alzheimer's Disease, Traumatic Brain Injury and Depression, sponsored by Avid Radiopharmaceuticals. Completed at 5 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-10.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 2, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
179
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.

Enrollment
5th of 22
179 · median 70
Started
2014
with 3 others
Phase 2
6 of 22
none open now
Registered
5th of 22
by date
Lead sponsor
15 of 22
Avid Radiopharmaceuticals

Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 5th largest by enrollment, is one of 4 that started in 2014, is one of 6 in phase 2, and was the 5th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About flortaucipir

flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing flortaucipir in Alzheimer Disease, or all of them as a file.
02

Study summary

This study is designed to expand the database of flortaucipir F 18 safety and tau binding as measured by PET imaging and to provide standardized conditions for flortaucipir PET use, data collection and analysis to facilitate companion studies including, but not limited to, longitudinal studies of aging, depression, and traumatic brain injury.

03

Conditions studied

  • Alzheimer's Disease
  • Traumatic Brain Injury
  • Depression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Subjects should meet inclusion and exclusion criteria for the companion protocol in addition to the criteria below.

Inclusion criteria

Inclusion Criteria:

  • Subjects who have a historical volumetric magnetic resonance imaging (MRI) as part of the companion study

Exclusion criteria

Exclusion Criteria:

  • Have cardiac, hepatic, renal, pulmonary, metabolic, or endocrine disturbances
  • Have a screening with a interval (QTc) > 450 msec if male or QTc > 470 msec if female
  • Have a history of additional risk factors for Torsades de Pointes (TdP) or are taking drugs known to cause QT-prolongation. Patients with a prolonged QTc interval in the setting of intraventricular conduction block may be enrolled with sponsor approval
  • Have a history of drug or alcohol dependence within the last year, or prior prolonged history of dependence unless approved by the sponsor
  • Are females of who are not surgically sterile, not refraining from sexual activity or not using reliable methods of
  • Have a history of relevant severe drug allergy or
  • Are patients who have received an medication within 30 days prior to the planned imaging session for this study
  • Are patients with current clinically significant unstable medical comorbidities
  • Are patients who have received a radiopharmaceutical for imaging or therapy within the past 24 hours prior to the imaging session for this study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
179 participants (actual)

Study arms

  • Experimental
    Flortaucipir PET Scans

    Drug: Flortaucipir F18 · Procedure: Brain PET scan

Interventions

  • IV injection, 370 MBq (10 mCi), up to two doses

    Also known as: [F-18]T807, 18F-AV-1451, LY3191748, Tauvid

  • ProcedureBrain PET scan

    positron emission tomography (PET) scan of the brain

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events Related to Flortaucipir Administration

    Frequency of treatment-emergent adverse events considered related to flortaucipir administration by the study investigator. Related events with a frequency \> 1.5% are reported. (note: all treatment-emergent adverse events, regardless of relatedness designation, are reported in "Adverse Events" section below).

    Time frame: within 48 hours of drug administration

  2. Flortaucipir PET Scan SUVr

    Standard Uptake Value Ratio (SUVr) using a weighted cortical average. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

    Time frame: baseline and follow-up scans

07

Results

Posted Sep 10, 2020

Participant flow

Participant flow — Overall Study
MilestoneCognitively ImpairedCognitively Normal
Started69110
Completed59110
Not completed100
Withdrew: Physician decision50
Withdrew: Withdrawal by subject50

Outcome measures

PrimaryNumber of Participants With Adverse Events Related to Flortaucipir Administration

Frequency of treatment-emergent adverse events considered related to flortaucipir administration by the study investigator. Related events with a frequency \> 1.5% are reported. (note: all treatment-emergent adverse events, regardless of relatedness designation, are reported in "Adverse Events" section below).

Time frame:
within 48 hours of drug administration
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Related to Flortaucipir Administration
ParticipantsCognitively ImpairedCognitively Normal
Headache03
Dysgeusia03
PrimaryFlortaucipir PET Scan SUVr

Standard Uptake Value Ratio (SUVr) using a weighted cortical average. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

Time frame:
baseline and follow-up scans
Reported as:
Mean · standardized uptake value ratio (SUVr)
Flortaucipir PET Scan SUVr
standardized uptake value ratio (SUVr)Cognitively ImpairedCognitively Normal
Baseline SUVr1.3983 ± 0.36411.004 ± 0.04871
Follow-up Scan SUVr1.4404 ± 0.37426—

Adverse events

Collected over AEs were collected at scan visit and for 48 hours after flortaucipir administration.. Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cognitively Impaired0/69 (0%)0/69 (0%)6/69 (8.7%)
Cognitively Normal0/110 (0%)0/110 (0%)16/110 (14.5%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventCognitively ImpairedCognitively Normal
headacheNervous system disorders0/695/110
blood pressure increasedInvestigations2/692/110
dysgeusiaNervous system disorders0/693/110
dry mouthGastrointestinal disorders0/692/110
injection site painGeneral disorders1/691/110
palpitationsCardiac disorders1/690/110
nasopharyngitisInfections and infestations1/690/110
insomniaPsychiatric disorders1/690/110
dizzinessNervous system disorders0/691/110
paraesthesiaNervous system disorders0/691/110

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cognitively ImpairedCognitively NormalTotal
Mean72.7 ± 7.670.4 ± 8.1871.3 ± 8.02
Sex: Female, Male
Sex: Female, Male(Participants)Cognitively ImpairedCognitively NormalTotal
Female3468102
Male354277
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cognitively ImpairedCognitively NormalTotal
Hispanic or Latino01010
Not Hispanic or Latino69100169
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cognitively ImpairedCognitively NormalTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander101
Black or African American5510
White62105167
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Cognitively ImpairedCognitively NormalTotal
United States69110179
MMSE
MMSE(score on a scale)Cognitively ImpairedCognitively NormalTotal
Mean21 ± 4.3529.3 ± 1.0626.1 ± 4.92
08

Study locations

5 sites
  • Banner Alzheimer's Institute
    Phoenix, Arizona 85006, United States
  • Yale University
    New Haven, Connecticut 06510, United States
  • Cleveland Clinic Lou Ruvo Center for Brain Health
    Las Vegas, Nevada 89106, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Center for Vital Longevity at the University of Texas at Dallas
    Dallas, Texas 75235, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Jun 2019, 54 months.

Results were first posted in Sep 2020, 1 year 2 months after primary completion.

Of 130 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 54 months is above that.

Counting every sponsor, half of 257 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2014
First posted
Oct 30, 2014
StartActual
Dec 2014
Primary completionActual
Jun 26, 2019
CompletionActual
Jun 26, 2019
Results first posted
Sep 10, 2020
Last update
Sep 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02278367
Responsible party
Sponsor
First posted
Oct 30, 2014
Start date
Dec 2014
Primary completion
Jun 26, 2019
Completion
Jun 26, 2019
Results posted
Sep 10, 2020
Last update
Sep 10, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion